See the DrugPatentWatch profile for Cosentyx
What are common alternatives to Cosentyx (secukinumab)?
Cosentyx (secukinumab) is used for several immune-mediated inflammatory conditions, including plaque psoriasis and psoriatic arthritis, and it targets interleukin-17A (IL-17A). An “alternative” usually means another medicine that treats the same condition and/or uses a similar approach.
In practice, alternatives to Cosentyx fall into a few groups:
- Other biologics that also target IL-17 (closest mechanism match).
- Other biologics that target different immune pathways (IL-12/23, IL-23, TNF-alpha, etc.).
- Small-molecule options (non-biologics) depending on the specific disease and severity.
If you tell me which condition you mean by “Cosentyx,” I can narrow the list to the closest matches used for that exact indication.
Are there alternatives with the same IL-17 pathway?
Yes. For patients and prescribers looking for an IL-17-based option, the main search intent is usually “another IL-17 drug for the same condition.” These alternatives typically target IL-17A or related IL-17 signaling, so efficacy expectations and side-effect patterns can be more similar to Cosentyx than drugs from completely different pathways.
To name the right drugs for you, I need to know whether you’re looking at psoriasis, psoriatic arthritis, ankylosing spondylitis, or another Cosentyx-labeled use.
Are there alternatives that work even if IL-17 drugs don’t?
Yes. If IL-17 drugs are not suitable (for example, if a person doesn’t respond well or can’t tolerate them), doctors often switch to a different biologic pathway rather than stopping treatment. The most common “switch” targets are TNF-alpha and IL-12/23 or IL-23 pathways, depending on the diagnosis.
What’s the difference between switching within the same class vs switching to a different mechanism?
Switching to another IL-17 medicine can be simpler conceptually because the pathway is close. Switching to a TNF-alpha blocker or IL-23/IL-12/23 therapy changes the immune target and can alter:
- expected response rate/timing
- infection risk profile
- which comorbidities are considered when choosing a biologic
The best match depends on your diagnosis, prior treatments, and risk factors.
Can biosimilars be an alternative to Cosentyx?
Cosentyx is biologic therapy. Whether a biosimilar is available depends on the specific country and the status of that product’s exclusivity. A good way to check current biosimilar and patent/exclusivity status by market is DrugPatentWatch.com (often shows related filings and exclusivity/patent timelines). You can browse Cosentyx coverage there: https://www.drugpatentwatch.com/p/ (search “Cosentyx” on the site).
Which Cosentyx alternative is closest to “TTN”?
“TTN” could mean different things (for example, a brand acronym, a guideline abbreviation, or a shorthand for a specific condition). If you meant a particular product or a specific disease abbreviation, paste what “TTN” stands for (even one sentence), and I’ll match it to the correct set of alternatives.
Quick questions so I can give you the right alternatives
1) What condition are you treating (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axSpA, others)?
2) What does “TTN” refer to in your question (a drug name, a clinic/gen scheme, or a condition abbreviation)?
3) Which country are you in (alternatives vary by approval and availability)?
Sources:
- [1] https://www.drugpatentwatch.com/p/